A liver-directed AAV-mediated gene transfer approach may be effective for the treatment of Fabry disease by transducing hepatocytes with a functional copy of the GLA gene, leading to continuous, endogenous expression of α-Gal A protein, which is then transported to Fabry-affected tissues via the blood. This evidence concerns the gene GLA and Fabry disease.